STOCK TITAN

Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

                                                                                                                                                                                                                                                                                                                                

Monthly information regarding the total number of voting rights and
total number of shares of the Company as of December 31, 2022

(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)

Market: NYSE Euronext Paris
ISIN Code: FR 0010417345



Date

Total number of sharesTotal number of voting rights
12/31/2022

94,137,145



Total gross of voting rights: 94,137,145



Total net* of voting rights: 93,966,891

* Total net = total number of voting rights attached to shares – shares without voting rights

Attachment


DBV Technologies

NASDAQ:DBVT

DBVT Rankings

DBVT Latest News

DBVT Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
France
Montrouge

About DBVT

dbv technologies is opening up a decisive new approach to the treatment of allergy – a major public health issue that is constantly increasing in prevalence. food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. dbv technologies (incorporated in 2002) has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. the viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. the product's clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. dbv technologies is focusing on food allergies (milk and